Q1 Earnings Estimate for Immunic Issued By William Blair

Immunic, Inc. (NASDAQ:IMUX) – Equities research analysts at William Blair issued their Q1 2025 earnings estimates for shares of Immunic in a report released on Wednesday, April 30th. William Blair analyst M. Minter anticipates that the company will post earnings per share of ($0.25) for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. William Blair also issued estimates for Immunic’s Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.22) EPS and FY2029 earnings at $1.05 EPS.

IMUX has been the subject of several other reports. B. Riley reiterated a “buy” rating and set a $6.00 price target on shares of Immunic in a report on Wednesday, April 16th. StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. D. Boral Capital reissued a “buy” rating and set a $17.00 price target on shares of Immunic in a research note on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Immunic in a research note on Thursday. One research analyst has rated the stock with a sell rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $13.20.

Immunic Price Performance

Shares of NASDAQ:IMUX opened at $1.15 on Friday. Immunic has a one year low of $0.83 and a one year high of $2.11. The company has a market cap of $110.19 million, a price-to-earnings ratio of -0.93 and a beta of 1.91. The firm has a 50 day simple moving average of $1.08 and a 200 day simple moving average of $1.11.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Focus Partners Wealth raised its stake in Immunic by 1.1% during the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock worth $2,168,000 after buying an additional 23,610 shares during the last quarter. 683 Capital Management LLC lifted its stake in shares of Immunic by 2.2% in the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock valued at $700,000 after purchasing an additional 15,349 shares during the period. Millennium Management LLC grew its stake in Immunic by 480.6% during the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock worth $580,000 after purchasing an additional 479,846 shares during the period. Renaissance Technologies LLC increased its holdings in Immunic by 45.6% in the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock worth $567,000 after purchasing an additional 177,542 shares in the last quarter. Finally, Bridgeway Capital Management LLC lifted its stake in Immunic by 11.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock valued at $215,000 after buying an additional 22,200 shares during the period. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.